Cite
HARVARD Citation
Lanfranconi, S. et al. (2023). Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet neurology. 22 (1), pp. 35-44. [Online].